Bed Bath & Beyond numbers lowered at Oppenheimer. Shares of BBBY now seen reaching $80, Oppenheimer said. Estimates also lowered on earnings release. Outperform rating.
Dollar General (DG) numbers upped at BofA/Merrill. DG estimates were boosted through 2013, Bank of America/Merrill Lynch said. Company should continue to show solid comp sales momentum. Buy rating and new $60 price target.
Equinix (EQIX) numbers raised at Jefferies. Shares of EQIX now seen reaching $200, Jefferies said. Estimates also raised on market expansion. Buy rating.
Mastercard (MA) estimates, target increased at Morgan Stanley. MA estimates were raised through 2014, Morgan Stanley said. Company has multiple potential growth drivers. Overweight rating and new $535 price target.Micron (MU) estimates, target cut at Sterne Agee. Shares of MU now seen reaching $10, according to Sterne Agee. Estimates also reduced, given lower pricing and retail demand. Buy rating. Onyx Pharmaceuticals (ONXX) numbers raised at Goldman. Shares of ONXX now seen reaching $63, according to Goldman Sachs. Estimates also increased, given expected FDA approval for the company's new blood cancer treatment. Buy rating. Onyx Pharmaceuticals numbers raised at Jefferies. Shares of ONXX now seen reaching $55, Jefferies said. Estimates also raised on Carfilzomib likely being approved. Hold rating. Procter & Gamble (PG) estimates lowered at Credit Suisse through 2014, Credit Suisse said. Company is seeing slower market growth and losing share. Outperform rating and $70 price target. Red Hat (RHT) numbers reduced at BMO. RHT estimates were cut through 2014, BMO Capital said. Billings growth has been disappointing. Outperform rating and new $60 price target. Red Hat target lowered at Citigroup to $66. Lower terminal multiple. Buy rating. Visa (V) estimates, target boosted at Goldman. Shares of V now seen reaching $147, according to Goldman Sachs. Estimates also upped, given better industry fundamentals. Overweight rating. Zumiez (ZUMZ) estimates, target raised at Credit Suisse. Shares of ZUMZ now seen reaching $41, according to Credit Suisse. Estimates also increased, as a recent acquisition in Europe should be accretive. Neutral rating. >To submit a news tip, email: email@example.com.
Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV